Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

VTAK US Equity

Catheter Precision, Inc.Health Care · Surgical & Medical Instruments & Apparatus · CIK 1716621 · FY ends Dec 31
$0.21
-0.01 (-4.31%)
USD · as of 2026-08-19 · marketstack
2 registered studies · 0 active

Studies where VTAK is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.

1 interventional · 1 observational

Held by 0 tracked-famous managers · FINRA short interest 1.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed

StudyPhaseStatusInterventionsConditionsEnrollmentPrimary completionUpdated
VIVO European Observational RegistryNCT04990089observationalMeasure the effectiveness of VIVO within different types of VA proceduresCompletedDevice: VIVOVentricular Arrythmia, Ventricular Tachycardia, Premature Ventricular Contraction1252024-06-28actual2025-01-31
VIVO™ Accuracy StudyNCT03340142Accuracy of correctly identifying PVC or VT originOpen-label · DiagnosticNot applicableCompletedDevice: VIVO™Premature Ventricular Contraction, Ventricular Tachycardia452018-09-04actual2018-11-15

Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.

Source: ClinicalTrials.gov, retrieved 2026-08-19